These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Two cases of renal cell carcinoma with ascites after interleukin-2 therapy]. Kobori G; Maegawa M; Ushida H; Maekawa S; Inoue K; Kaneko Y; Ohmori K; Nishimura K Hinyokika Kiyo; 2002 Jul; 48(7):455-7. PubMed ID: 12229188 [TBL] [Abstract][Full Text] [Related]
3. High-dose interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma: still the standard. Dutcher JP Oncology (Williston Park); 2011 Apr; 25(5):427-8. PubMed ID: 21710841 [No Abstract] [Full Text] [Related]
4. Correlation between clinical response to interleukin 2 and HLA phenotypes in patients with metastatic renal cell carcinoma. Bain C; Merrouche Y; Puisieux I; Blay JY; Negrier S; Bonadona V; Lasset C; Lanier F; Duc A; Gebuhrer L; Philip T; Favrot MC Br J Cancer; 1997; 75(2):283-6. PubMed ID: 9010039 [TBL] [Abstract][Full Text] [Related]
5. Response of papillary renal cell carcinoma in a solitary kidney to high dose interleukin therapy. Diner EK; Linehan M; Walther M Int J Urol; 2005 Nov; 12(11):996-7. PubMed ID: 16351658 [TBL] [Abstract][Full Text] [Related]
6. Successful treatment of a patient on adrenal steroid replacement therapy with high-dose bolus interleukin-2 for metastatic renal cell carcinoma. Deshpande H; Dutcher JP; Novik Y; Oleksowicz L Cancer J Sci Am; 1999; 5(1):52-3. PubMed ID: 10188062 [No Abstract] [Full Text] [Related]
7. Metastatic renal cell cancer--is the outlook really improving? Waxman J; Thomas H Postgrad Med J; 1990 Jun; 66(776):435-40. PubMed ID: 1699216 [No Abstract] [Full Text] [Related]
13. Metastatic renal cell cancer treated with low-dose interleukin-2. A phase-II multicentre study. Stoter G; Fosså SD; Rugarli C; Symann M; Jasmin C; Israel L; Bijman JT; Palmer P; Franks CR; Philip T Cancer Treat Rev; 1989 Jun; 16 Suppl A():111-3. PubMed ID: 2670207 [No Abstract] [Full Text] [Related]
14. Transfusion-related acute lung injury (TRALI) following platelet transfusion in a patient receiving high-dose interleukin-2 for treatment of metastatic renal cell carcinoma. Medeiros BC; Kogel KE; Kane MA Transfus Apher Sci; 2003 Aug; 29(1):25-7. PubMed ID: 12877889 [TBL] [Abstract][Full Text] [Related]
15. Sustained ventricular tachycardia and its successful prophylaxis during high-dose bolus interleukin-2 therapy for metastatic renal cell carcinoma. Oleksowicz L; Escott P; Leichman GC; Spangenthal E Am J Clin Oncol; 2000 Feb; 23(1):34-6. PubMed ID: 10683072 [TBL] [Abstract][Full Text] [Related]
16. [Systemic immunotherapy of metastatic renal cell carcinoma and long-term outcome]. Brinkmann OA; Roigas J; Hertle L Urologe A; 2002 May; 41(3):231-8. PubMed ID: 12132272 [TBL] [Abstract][Full Text] [Related]
17. Phase II trial of sequential radiation and interleukin 2 in the treatment of patients with metastatic renal cell carcinoma. Redman BG; Hillman GG; Flaherty L; Forman J; Dezso B; Haas GP Clin Cancer Res; 1998 Feb; 4(2):283-6. PubMed ID: 9516912 [TBL] [Abstract][Full Text] [Related]